TABLE 2.

Effect of prophylactic drug candidates on the occurrence of cisplatin‐induced ARF using the FAERS data analysis

Drug	ARF (%) without the drug	ARF (%) with the drug	ROR (95% CI)	p Value
Fenofibrate	8.81 (2324/26379)	3.45 (2/58)	0.39 (0.05–1.48)	0.236
Diltiazem	7.54 (2009/26662)	6.98 (6/86)	0.93 (0.33–2.10)	1
Metoprolol	7.53 (1994/26474)	7.66 (21/274)	1.02 (0.33–2.10)	0.909
Vorinostat	8.80 (2320/26375)	9.68 (6/62)	1.10 (0.39–2.54)	0.822
Cyclosporine	8.78 (2315/26371)	16.67 (11/66)	1.90 (0.90–3.63)	0.056

Note: Among the 10 drugs extracted by the LINCS analysis, there were five drugs for which FAERS analysis was possible. Among these, fenofibrate had an ROR <1 in the FAERS analysis, and the number of reports of cisplatin‐induced renal injury was significantly lower than reports without fenofibrate. Statistical analysis was conducted using Fisher’s exact test.

Abbreviations: ARF, acute renal failure; CI, confidence interval; FAERS, US Food and Drug Administration Adverse Event Reporting System; LINCS, Library of Integrated Network‐based Cellular Signatures; ROR, reporting odds ratio.